Portada Simposios - Supplements - Haematologica

210 Haematologica (ed. esp.), volumen 85, supl. 2, octubre 2000
9. Farmer RDT, Todd JC, Lewis MA, Mac Rae KD, Willians TJ et al. The risk
of venous thromboemlolic disease amongst German women using oral
contraceptives: a database study. Contraception 1998; 57: 67-70.
10. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous
thromboembolism. A case control study. Contraception 1998; 57:
291-301.
11. Mann JI, Vessey MP, Thorogood M, Doll R. Myocardial infarction in
young women with special reference to oral contraceptive practice. BMJ
1975; 2: 241-245.
12. Sidney S, Petitti DB, Quesenberry CP, Klatskey AL, Ziel HK, Wolf S.
Myocardial infarction in users of low dose oral contraceptives. Obstet
Gynecol 1996; 88: 939-944.
13. Throrogood M. Oral contraceptives and myocardial infarction: new evidence
leaves unanswered questions. Thromb Haemostas 1997; 78:
327-333.
14. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke
in users of low dose oral contraceptives. N Engl J Med 1996; 335: 8-15.
15. Heinemann LAJ, Lewis MA, Thorogood M et al. Oral contraceptives
and risk of thromboembolic stroke: results from the Transnational
study on oral contraceptives and health of young women. BMJ 1997;
315: 1502-1504.
16. Lidegaard O, Kreiner S. Cerebral thrombosis and oral contraceptives.
A case control study. Contraception 1998; 57: 303-314.
17. De Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case control
study of risk of cerebral sinus thrombosis in oral contraceptive users
and in carriers of hereditary prothrombotic conditions. The cerebral venous
sinus thrombosis study group. BMJ 1998; 316: 589-592.
18. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Manucci PM. High risk
of cerebral vein thrombosis in carriers of a prothrombin gene mutation
and in users of oral contraceptives. N Engl J Med 1998; 338:
1793-1797.
19. Heinemann LA, Lewis MA, Spitzer WO,Thorogood M, Guggenmoos-Holzman
J, Bruppacher R. Thromboembolic stroke in young women.
A European case control study on oral contraceptives. Transnational
Research Group on Oral Contraceptives and the Health of Young
Women. Contraception 1998; 57: 29-37.
20. Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton
IR. Oral contraceptives and venous thromboembolic disease. The findings
from database studies in the United Kingdom and Germany. Am
J Obs Gynecol 1998; 179: 3 (Supl) 578-586.
21. Gilabert J. Anticoncepcion hormonal oral (AHO) y hemostasia. Conferencia
de Cosumo. Prescripción y manejo de anticonceptivos hormonales
orales Grupo Aula Médica Ediciones. Madrid 2000.
22. Rosin J, Tans G. Nicolaes GAF, Thomassen MC, van Oerle R, van der
Ploeg PM, Heijnen P, Hamulyak K, Hemker MC. Oral contraceptives
and venous thrombosis: diferent sensitivites to activated protein C in
women using second and third generation oral contraceptives. Br J
Haematol 1997; 17: 233-238.
23. Mammen Ef. Oral contraceptives and blood coagulation a critical review.
Am J Obstet Gynecol 1982; 142: 781-790.
24. Poller L, Thompson JM. Clotting factors during oral contraception further
report. B Med J 1968; 2: 23-26.
25. Meade TW, Brozovic M, Chakrabarth R, Howarth DJ, North WRS, Stirling
Y. Epidemiological study of the haemostatic and other effects of
oral contraceptives. Brit J Haematol 1976; 34: 353-364.
26. Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, Vandenbroucke
JP. Venous thrombosis, oral contraceptives and high factor VIII levels.
Thromb Haemost 1999; 82: 1024-1027.
27. Klut C, Lansink M. Effect of oral contraceptives on haemostasis variables.
Thromb Haemost 1997; 78: 315-326.
28. Norris LA, Bonnar J. Haemostatic changes and the oral contraceptive
pill. Obstet Gynaecol 1997; 11: 545-564.
29. Winkler UH. Blood coagulation and oral contraceptives. A critical review.
Contraception 1998; 57: 203-209.
30. Gilabert J, Fernandez JA, España F, Aznar J, Estelles A. Physiological cagulation
inhibitors (protein S, protein C and antithrombin III) in severe
preeclamptic states and in users of oral contraceptives. Thromb Res
1988; 49: 319-329.
31. Pabinger I, Schneider B and the GTH study group on natural inhibitors.
Thrombosis risk of women with hereditary antithrombin III, protein C
and protein S deficiency taking oral contraceptive medication. Thromb
Haemost 1994; 71: 548-552.
32. Quehenberger P, Loner V, Kapiotis S, Handler S, Schneider B, Huber J,
Speiser W. Increased levels of activated factor VII and decrease plasma
protein S activity and circulating thrombomodulin during use of oral
contraceptives. Thromb Haemost 1996; 76: 729-734.
33. Robinson GE. Low dose combined oral contraceptive. Br J Obstet Gynaecol
1994; 101: 1036-1041.
34. Fotherby K, Caldwell ADS. New progestogens in oral contraception.
Contraception 1994; 49: 1-32.
35. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke
JP. Enhancement by factor V Leiden mutation of risk of
deep vein thrombosis associated with oral contraceptives containing a
third-generation progesterone. Lancet 1995; 346: 1593-1597.
36. Sperof L. Oral contraceptives and venous thromboembolism. Int J Gynecol
Obstet 1996; 54: 45-50.
37. Weiss G. Risk of venous thromboembolism with third generation oral
contraceptives: a review. Am J Obstet Gynecol 1999; 180 (2 Pt 2):
295-301.
38. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism
among new users of different oral contraceptives. Lancet 1999; 354:
127-128.
39. Daume E. Influence of modern low dose oral contraceptives on hemostasis.
Adv Contraception 1990; 6 Supl: 51-68.
40. Bloemenkamp KW, Gevers Leuven JA, Helmerhorst FM,Dersjant-Roordamc
MC, de Boer R, Kluft C. In low dose oral contraceptives containing
20 g or 30 g ethinyl-estradiol, gestodene is associated with a lower
increase in coagulant factor VII than in desogestrel. Gynecol Endocrinol
1996; 10 (Supl. 2): 145-148.
41. Norris LA, Bonnar J. Estrogen dose and progestogen type: their effect
on hemostatic changes in oral contraceptive users. Gynecol Endocrinol
1996; 10 (Supl. 2): 133-135.
42. Andersen BS, Olsen J, Nielsen GL, Steffensen FH, Sorensen HT, Baech J,
Gregersen H. Third generation oral contraceptives and heritable thrombophilia
as risk factors of non fatal venous thromboembolism.
Thromb Haemost 1998; 79: 28-31.
43. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a
previously unrecognized mechanism characterized by poor anticoagulant
response to activated protein C. Prediction of a cofactor to activated
protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
44. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic
variant in the 3’ untranslated region of the prothrombin gene is associated
with elevated plasma prothrombin levels and increase in venous
thrombosis. Blood 1996; 88: 3698-3703.
45. Bertina RM. Factor V Leiden and other coagulation factor mutations
affecting thrombotic risk. Clin Chem 1997; 43: 1678-1683.
46. Hillarp A, Zoller B, Svensson JP, Dahlbäck B. The 20210A allele of the
prothrombin gene is a common risk factor among swedish outpatients
with verified deep venous thrombosis. Thromb Haemost 1997; 78:
990-992.
47. Arruda VR, Annichino-Bizzachi JM, Goncalves MS, Costa FF. Prevalence
of the prothrombin gene variant (nt 20210A) in venous thrombosis
and arterial disease. Thromb Haemost 1997; 78: 1430-1433.
48. Vandenbroucke JP, Koster T, Briët E, Reitsma Ph, Bertina Rm, Rosendaal
FR. Increased risk of venous thrombosis in oral contraceptive users
who are carriers of the factor V Leiden mutation. Lancet 1994; 344:
1453-1457.
49. Olivieri O, Friso S, Manzato F et al. Resistance to activated protein C
in healthy women taking oral contraceptives. Haematol 1995; 91:
465-470.
50. Rintelen C, Mannhalter CH, Ireland H, Lane DA, Knöbl P, Lechner K,
Pabinger I. Oral contraceptives enhance the risk of clinical manifestation
of venous thrombosis at a young age in females homozygous for
factor V Leiden. Br J Haematol 1996; 93: 487-490.
51. Gould J, Deam S, Dolan G. Prothrombin 20210A polymorphism and thrird
generation oral contraceptives.A case report o coeliac axis thrombosis
and splenic infarction. Thromb Haemost 1998; 79: 1214-1215.
52. Bennet L, Odeberg H. Resistance to activate protein C, highly prevalent
amongst users of oral contraceptives with venous thromboembolism.
J Int Med 1998; 244: 27-32.
53. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction
between the G20210A mutation of the prothrombin gene and oral
contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc
Biol 1999; 19: 700-703.
54. Aznar J, Vayá A, Estellés A, Mira Y, Seguí R, Villa P, Ferrando F, Falcó C,
Corella D, España F. Risk of venous thrombosis in carriers of the prothrombin
G20210A variant and factor V Leiden and their interaction with
oral contraceptives. Hematologia (en prensa).
55. Mira Y, Aznar J, Estellés A, Vayá A, Villa P, Ferrando F. Congenital and
acquired thrombotic risk factors in women using oral contraceptives
clinical aspects. Clin Appl Thrombosis Hemostasis 2000; 6: 162-167.
56. Aznar J, Gilabert J. Oral contraceptive user and screening of factor V Leiden.
Thrombosis and Haemostasis 1999; 81: 845-846.
TERAPIA HORMONAL
SUSTITUTIVA Y MODIFICACIONES
DE LA HEMOSTASIA
A. ESTELLÉS 1 , C. FALCÓ 1 , F. ESPAÑA 1 Y J. AZNAR 2
1 Centro de Investigación. 2 Departamento de Biopatología
Clínica. Hospital La Fe. Valencia.
Introducción
La menopausia supone un estado de disminución
estrogénica que origina una serie de cambios, tanto
en el perfil lipídico como en el flujo sanguíneo y en la
hemostasia, que pueden favorecer el desarrollo de la
enfermedad cardiovascular 1-5 .
Las modificaciones que se observan en la menopausia
debidas al déficit de estrógenos se pueden